Clinical Subject Page
Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic malignancy caused by uncontrolled proliferation of immature lymphoid precursor cells (lymphoblasts) in the bone marrow. It is the most common childhood cancer but can also occur in adults
Also called
Acute Lymphoid Leukemia
ICD-10
C91.0
Specialty
Hematology
Onset
Acute
Reviewed
August 2026
On This Page
-
OverviewOverview
-
Etiology & Risk FactorsEtiology & Risk Factors
-
PathophysiologyPathophysiology
-
Clinical PresentationClinical Presentation
-
History TakingHistory Taking
-
Physical ExaminationPhysical Examination
-
InvestigationsInvestigations
-
DiagnosisDiagnosis
-
ManagementManagement
-
ComplicationsComplications
-
PrognosisPrognosis
-
Key Points / Clinical PearlsKey Points / Clinical Pearls
Overview
Acute Lymphoblastic Leukemia (ALL) results from malignant transformation of immature B-cell or T-cell lymphoid precursors. The abnormal lymphoblasts rapidly accumulate in the bone marrow and suppress normal hematopoiesis, causing anemia, thrombocytopenia, and neutropenia. ALL can also infiltrate the CNS, lymph nodes, spleen, liver, and testes.
Etiology & Risk Factors
-Etiology
The exact cause is usually unknown. Acute Lymphoblastic Leukemia (ALL) develops through acquired genetic abnormalities that cause uncontrolled proliferation and impaired differentiation of lymphoid precursor cells.
-Risk Factors
Childhood age
Previous chemotherapy or radiotherapy
Ionizing radiation
Genetic syndromes, especially:
Down syndrome
Li-Fraumeni syndrome
Neurofibromatosis type 1
Ataxia-telangiectasia
Previous hematologic disorders
Pathophysiology
Genetic abnormalities in lymphoid precursor cells → uncontrolled proliferation of immature lymphoblasts → accumulation of lymphoblasts in bone marrow → suppression of normal erythropoiesis, granulopoiesis, and megakaryopoiesis → anemia, neutropenia, and thrombocytopenia → infiltration of lymphoblasts into lymph nodes, liver, spleen, CNS, and other tissues.
Clinical Presentation
Symptoms
Fatigue
Pallor
Fever
Recurrent infections
Easy bruising
Bleeding
Bone or joint pain
Weight loss
Loss of appetite
Headache
Vomiting
Abdominal fullness
Signs
Pallor
Fever
Petechiae
Ecchymoses
Lymphadenopathy
Hepatomegaly
Splenomegaly
Bone tenderness
CNS abnormalities
Testicular enlargement in some cases
History Taking
-Ask about:
- Fatigue
- Fever
- Recurrent infections
- Bleeding
- Easy bruising
- Bone or joint pain
- Weight loss
- Night sweats
- Headache
- Vomiting
- Neurological symptoms
- Abdominal fullness
- Testicular symptoms
- Previous chemotherapy/radiotherapy
- Family history
- Genetic syndromes
Physical Examination
-General Examination
Look for:
Pallor
Fever
Weight loss
Petechiae
Ecchymoses
Lymph Node Examination
Assess for:
Cervical lymphadenopathy
Axillary lymphadenopathy
Inguinal lymphadenopathy
-Abdominal Examination
Look for:
Hepatomegaly
Splenomegaly
-Musculoskeletal Examination
Assess for:
Bone tenderness
Joint tenderness
Reduced mobility
-Neurological Examination
Look for:
Cranial nerve abnormalities
Headache
Focal neurological deficits
Signs of raised intracranial pressure
Investigations
-Complete Blood Count (CBC)
May show:
Anemia
Thrombocytopenia
Neutropenia
Leukocytosis, normal WBC, or leukopenia
Circulating lymphoblasts
-Peripheral Blood Film
May show:
Lymphoblasts
Anemia
Thrombocytopenia
Abnormal white cell count
-Bone Marrow Aspiration and Biopsy — Gold Standard
Typical findings:
Increased lymphoblasts
≥20% lymphoblasts in the bone marrow supports the diagnosis of acute leukemia
-Flow Cytometry
Used to determine lineage:
B-cell ALL
Common markers:
CD19
CD20
CD22
CD79a
CD10
TdT
T-cell ALL
Common markers:
CD2
CD3
CD5
CD7
TdT
Cytogenetic & Molecular Testing
Important abnormalities include:
BCR-ABL1 (Philadelphia chromosome)
ETV6-RUNX1
KMT2A rearrangement
Hyperdiploidy
Hypodiploidy
These abnormalities have important prognostic and therapeutic implications.
CNS Evaluation
Lumbar puncture with cerebrospinal fluid examination
Usually performed as part of staging and treatment planning
Additional Investigations
Urea and electrolytes
Creatinine
Liver function tests
LDH
Uric acid
Coagulation profile
Blood group and crossmatch
Baseline cardiac assessment before anthracyclines
Infection screening before chemotherapy
Diagnosis
Diagnosis is based on:
- CBC and peripheral blood findings
- Bone marrow examination
- Increased lymphoblasts
- Flow cytometry confirming lymphoid lineage
- Cytogenetic and molecular testing
Further classification determines:
- B-cell ALL
- T-cell ALL
- Genetic/molecular subtype
Management
Acute Lymphoblastic Leukemia (ALL) requires multi-phase combination chemotherapy.
Induction
Goal:
Achieve complete remission
Common agents include:
Vincristine
Corticosteroid
Anthracycline
Asparaginase
Additional agents are used according to risk group and protocol.
Consolidation / Intensification
Goal:
Eliminate residual leukemic cells and Reduce relapse risk
Multiple chemotherapy agents are used according to the treatment protocol.
Maintenance
Usually prolonged therapy with:
6-mercaptopurine
Methotrexate
CNS-Directed Therapy
Because the CNS can act as a sanctuary site:
Intrathecal chemotherapy is essential
Methotrexate ± cytarabine depending on protocol
Cranial radiotherapy is reserved for selected high-risk situations
Relapsed / Refractory ALL
Options include:
Salvage chemotherapy
Blinatumomab
Inotuzumab ozogamicin
CAR T-cell therapy in selected B-cell ALL
Allogeneic hematopoietic stem cell transplantation
Supportive Care
Infection prevention and treatment
Blood and platelet transfusions
Tumor lysis syndrome prophylaxis
Antiemetics
Fertility preservation when appropriate
Nutritional support
Complications
- Severe anemia
- Severe infections
- Bleeding
- Tumor lysis syndrome
- CNS involvement
- Testicular involvement
- Treatment-related toxicity
- Relapse
- Secondary malignancies
- Infertility
Prognosis
Prognosis is generally excellent in children, with modern treatment achieving very high cure rates. Outcomes in adults are less favorable but have improved substantially with risk-adapted therapy, targeted treatments, and immunotherapies. Prognosis depends on age, initial WBC count, genetic abnormalities, CNS involvement, and minimal residual disease (MRD) response
Key Points / Clinical Pearls
- Acute Lymphoblastic Leukemia (ALL) is a malignancy of immature lymphoid cells.
- It is the most common childhood cancer.
- It may be B-cell or T-cell lineage.
- Common presentation: pallor + fever + infections + bleeding + bone pain.
- CBC may show anemia, thrombocytopenia, and abnormal WBC count.
- Bone marrow examination confirms the diagnosis.
- Flow cytometry determines lineage.
- Cytogenetic/molecular testing is essential for risk stratification.
- CNS-directed therapy is an essential component of treatment.
- Treatment consists of induction → consolidation/intensification → maintenance.
- BCR-ABL1-positive ALL requires a tyrosine kinase inhibitor.
- MRD is an important prognostic and treatment-response marker.
- Puckett Y, Chan O. National Center for Biotechnology Information (NIH). Acute Lymphocytic Leukemia, StatPearls.
- National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Acute Lymphoblastic Leukemia, 2025.
- Abou Dalle I, Moukalled N, El Cheikh J, Mohty M, Bazarbachi A. Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia: Ten Frequently Asked Questions. Leukemia. 2024;38:1876-1884.
- National Cancer Institute (NIH). Adult Acute Lymphoblastic Leukemia Treatment (PDQ), Health Professional Version.
- MedlinePlus, National Library of Medicine (NIH). Acute Lymphocytic Leukemia: Medical Encyclopedia.